Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GRC 54276,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Glenmark Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Ichnos and Glenmark Collaborate for Innovation in Cancer Treatment
Details : The collaboration between Ichnos and Glenmark aims to enhance cancer drug discovery, focusing on novel biologics and small molecules like GRC 54276 for hematological malignancies.
Brand Name : GRC 54276
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 30, 2024
Lead Product(s) : GRC 54276,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Glenmark Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : STAR-0310
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Astria Therapeutics
Deal Size : $320.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the license agreement, Astria plans to develop the lead candidate, called STAR-0310, a monoclonal antibody OX40 antagonist that incorporates YTE half-life extension technology, for the treatment of AD.
Brand Name : STAR-0310
Molecule Type : Large molecule
Upfront Cash : $15.0 million
October 11, 2023
Lead Product(s) : STAR-0310
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Astria Therapeutics
Deal Size : $320.0 million
Deal Type : Licensing Agreement
Ichnos Sciences Receives Orphan Drug Designation for First-in-class Trispecific Antibody, ISB 2001
Details : ISB 2001, Ichnos' third clinical-stage asset to receive ODD for the treatment of multiple myeloma, is the company's first BCMA x CD38 x CD3 TREAT™ trispecific antibody based on the company's proprietary BEAT® platform, which enables the development of...
Brand Name : ISB 2001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 07, 2023
Lead Product(s) : ISB 1442
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ISB 1442 is a biparatopic 2+1 BEAT® bispecific antibody targeting CD38 and CD47, for the treatment of acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL).
Brand Name : ISB 1442
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 21, 2023
Lead Product(s) : ISB 1442
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ISB 1442
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ichnos Sciences Announces Initiation Of First-In-Human Study For ISB 1442
Details : ISB 1442 is a biparatopic bispecific antibody that combines two proprietary anti-CD38 binding arms, each targeting different regions on CD38, with an antagonistic anti-CD47 arm, making it equivalent to a trispecific antibody.
Brand Name : ISB 1442
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 28, 2022
Lead Product(s) : ISB 1442
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ISB 2001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In vitro studies showed that ISB 2001 exhibited increased killing potency of tumor cells compared to all tested antibodies that are either currently approved therapeutics for multiple myeloma or being tested in ongoing clinical studies.
Brand Name : ISB 2001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 09, 2022
Lead Product(s) : ISB 2001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ISB 880
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Almirall
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Almirall is granted global rights to develop and commercialize ISB 880, monoclonal antibody for autoimmune diseases. Ichnos will retain rights for antibodies acting on the IL-1RAP pathway for oncology indications.
Brand Name : ISB 880
Molecule Type : Large molecule
Upfront Cash : $23.6 million
December 14, 2021
Lead Product(s) : ISB 880
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Almirall
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Telazorlimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Glenmark Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The two highest doses of telazorlimab, 300 mg and 600 mg administered every two weeks, were statistically superior to placebo. Telazorlimab was well-tolerated during the study to date.
Brand Name : ISB 830
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 03, 2021
Lead Product(s) : Telazorlimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Glenmark Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?